MINIMED GROUP INC
MMEDNASDAQTrading Snapshot
- Day Range
- $19.75 – $20.24
- 52-Week Range
- $10.65 – $24.43
- Volume
- $2.91B
- Avg Volume
- $2.62B
- Shares Outstanding
- 280.8M
- Next Earnings
- Oct 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $3.10B
- Last Q Revenue
- $843M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
- Dilution (1yr)
- +0.0%
Why Investors Own MMED
- ✓High-growth profile — revenue up +39.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 51% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MINIMED GROUP INC
MMED
StockOtter · stockotter.spaceAbout MINIMED GROUP INC
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, specialized software platforms, and various supplementary accessories. These innovations are crafted to enable both patients and healthcare providers to accurately monitor and precisely regulate blood glucose levels. The enterprise was established in 1983 by Alfred E. Mann and is currently headquartered in Northridge, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary
NORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Sheila Denton has been named General Counsel & Corporate Secretary.
Squeeze Watch: 10 Stocks With Over 33% Short Interest
Ten stocks worth more than $2 billion each have more than a third of their float sold short. At the top of the list, one company has more than 80% of its float sold short.
MiniMed Group, Inc. (MMED) Presents at Bank of America Global Healthcare Conference 2026 Transcript
MiniMed Group, Inc. (MMED) Presents at Bank of America Global Healthcare Conference 2026 Transcript
MiniMed Group Inc (NASDAQ:MMED) Receives Consensus Recommendation of “Moderate Buy” from Analysts
MiniMed Group Inc (NASDAQ: MMED - Get Free Report) has earned a consensus rating of "Moderate Buy" from the sixteen brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock
Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc.
Medtronic shareholders can exchange their Medtronic ordinary shares for shares of MiniMed Provides Medtronic shareholders with option for a generally tax-free exchange for U.S. federal income tax purposes GALWAY, Irela
MiniMed Files Form S-4 Registration Statement in Connection with Medtronic Exchange Offer Announcement
NORTHRIDGE, Calif., Sept. 14, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) announced that it has filed a Form S-4 Registration Statement today with the Securities and Exchange Commission (the "SEC") in connection with Med